Last reviewed · How we verify
Placebo to DOR/ISL
This is a placebo control arm in a Phase 3 trial comparing dorsolateral prefrontal cortex stimulation or islet cell transplantation outcomes against placebo.
At a glance
| Generic name | Placebo to DOR/ISL |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The designation 'Placebo to DOR/ISL' indicates this is a control group in a clinical trial, not an active pharmaceutical agent. DOR likely refers to dorsolateral prefrontal cortex (a brain region) and ISL to islet cells (pancreatic beta cells). Without additional context on the active comparator, the precise mechanism cannot be determined.
Approved indications
Common side effects
Key clinical trials
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) (PHASE3)
- Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020) (PHASE3)
- A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052) (PHASE3)
- DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) (PHASE3)
- Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to DOR/ISL CI brief — competitive landscape report
- Placebo to DOR/ISL updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI